Hydroxychloroquine lower dose for Retinitis Pigmentosa
This trial is testing whether the drug hydroxychloroquine can help people with retinitis pigmentosa by altering the autophagy pathway in photoreceptors.
- Retinitis Pigmentosa
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Are enrollments still open for this investigation?
"As stated on clinicaltrials.gov, this medical investigation is presently enrolling volunteers. The trial was first announced on February 25th 2020 and the most recent update came out February 14th 2022."
How many participants are currently enlisted in this clinical investigation?
"Affirmative. Clinicaltrials.gov provides evidence that this research project is recruiting participants, having been first posted on February 25th 2020 and most recently updated on February 14th 2022. The trial requires a total of twelve subjects from one site to participate."